Immatics Announced At ESMO Saturday, Updated Phase 1b IMA402 Data Showing 32% Confirmed Response Rate, 12.5-Month Median Duration Of Response And 91% One-Year Overall Survival Rate In Advanced Melanoma Patients With High PRAME Expression
Share
Why It Matters
Immatics shared early test results for a new cancer medicine. The treatment helped about one third of patients, which doctors watch to see if the company is on the right track.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.